NCT00550615 2023-09-26Dasatinib in Relapsed or Refractory Non-Hodgkin's LymphomaUniversity of NebraskaPhase 1/2 Completed38 enrolled 9 charts
NCT00608361 2015-07-02Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By SurgeryNational Cancer Institute (NCI)Phase 1 Completed80 enrolled